Clinical Trials

Mycophenolate mofetil levels in myasthenia gravis

Assess for any correlation between mycophenolate mofetil (MMF) serum levels and the response to therapy in myasthenia gravis patients

To correlate the clinical response with MMF serum levels in myasthenia gravis patients who are receiving this immunosuppressive agent.


Diagnosis of MG, greater than age 18 years, on stable doses of MMF for three months. Patients who have been on MMF for less than 2 years will be enrolled.


Serum levels will be drawn and simple, non-invasive outcome measures will be performed in eligible myasthenia gravis patients. Patients will be assessed approximately 3 times over a 12 month period.




Nicholas J. Silvestri, Gil I. Wolfe

Contact Information

Name: Kara Patrick
Phone: 716-859-3639